Document:

Exhibit

Exhibit 4.4
Execution Version

THIRD SUPPLEMENTAL INDENTURE
THIRD SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of July 17, 2018, among Thermal Canada Infrastructure Holdings LLC (the “Guaranteeing Subsidiary”), a subsidiary of NRG Yield Operating LLC (or its permitted successor), a Delaware limited liability company (the “Company”), the Company, the other Guarantors (as defined in the Indenture referred to herein) and Delaware Trust Company (as successor in interest to Law Debenture Trust Company of New York), as trustee under the Indenture referred to below (the “Trustee”).
W I T N E S S E T H
WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the “Indenture”), dated as of August 18, 2016 providing for the issuance of 5.000% Senior Notes due 2026 (the “Notes”);
WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall fully and unconditionally guarantee all of the Company’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Subsidiary Guarantee”); and
WHEREAS, pursuant to Sections 4.10 and 9.01 of the Indenture, the Trustee, the Company and the other Guarantors are authorized to execute and deliver this Supplemental Indenture.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiary and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:
1.CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.
2.    AGREEMENT TO GUARANTEE. The Guaranteeing Subsidiary hereby becomes party to the Indenture as a Guarantor and as such will have all the rights and be subject to all the Obligations and agreements of Guarantors under the Indenture. The Guaranteeing Subsidiary hereby agrees to provide a full and unconditional Guarantee on the terms and subject to the conditions set forth in the Subsidiary Guarantee and in the Indenture including but not limited to Article 10 thereof.
3.    NO RECOURSE AGAINST OTHERS. No director, officer, employee, incorporator or stockholder of the Company or any Guarantor, as such, will have any liability for any obligations of the Company or the Guarantors under the Notes, this Indenture, the Subsidiary Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. The waiver may not be effective to waive liabilities under the federal securities laws.
4.    NEW YORK LAW TO GOVERN. THE INTERNAL LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.
5.    COUNTERPARTS. The parties may sign any number of copies of this Supplemental Indenture.  Each signed copy shall be an original, but all of them together represent the same agreement.
6.    EFFECT OF HEADINGS. The Section headings herein are for convenience only and shall not affect the construction hereof.

38282987

7.    THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiary and the Company.
8.    RATIFICATION OF INDENTURE; SUPPLEMENTAL INDENTURE FOR ADDITIONAL GUARANTEES PART OF INDENTURE. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture for Additional Guarantees shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall by bound hereby.

2

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written.
	
	
	

THERMAL CANADA INFRASTRUCTURE HOLDINGS LLC

	

By:   /s/ Chad Plotkin        
Name: Chad Plotkin
Title: Vice President & Treasurer

	

NRG YIELD OPERATING LLC
NRG YIELD LLC
NRG YIELD DGPV HOLDING LLC

By:     /s/ Chad Plotkin      
Name: Chad Plotkin
Title: Senior Vice President, Chief Financial Officer & Treasurer

ALTA WIND 1-5 HOLDING COMPANY, LLC
ALTA WIND COMPANY, LLC
CENTRAL CA FUEL CELL 1, LLC
NRG SOLAR IGUANA LLC
NRG SOLAR LAS VEGAS MB 1 LLC
NRG SOLAR STAR LLC
NRG SOLAR TABERNACLE LLC
NRG SOUTH TRENT HOLDINGS LLC  
NRG YIELD RPV HOLDING LLC
NYLD FUEL CELL HOLDINGS LLC
PORTFOLIO SOLAR I, LLC
SOLAR FLAGSTAFF ONE LLC
SPP ASSET HOLDINGS, LLC
SPP FUND II HOLDINGS, LLC
SPP FUND II, LLC
SPP FUND II-B, LLC
SPP FUND III, LLC
THERMAL INFRASTRUCTURE DEVELOPMENT HOLDINGS LLC
UB FUEL CELL, LLC

By:     /s/ Chad Plotkin      
Name: Chad Plotkin
Title: Vice President & Treasurer
DELAWARE TRUST COMPANY

By:   /s/ Thomas Musarra       
   Authorized Signatory:

	 

[Signature Page to Third Supplemental Indenture]Exhibit
10.1

 

CONSULTING
AGREEMENT

 

This
Consulting Agreement (this “Agreement”) is hereby made and entered into as of the 2nd day of April, 2018 (the “Effective
Date”) by and between Liberi Life Sciences Consultancy BV (“Advisor”), represented by Drs. Frans Trouwen, (Heemsteedse
Dreef 159, 2101KD Heemstede, The Netherlands) and , Lixte Biotechnology Holdings, Inc. (“COMPANY”) with its principal
place of business at 248 Route 25A No. 2, East Setauket, NY 11733, represented by John Kovach M.D.

 

RECITALS

 

A.
Advisor represents itself as having the ability, experience and resources to provide consulting and advisory services to COMPANY.

 

B.
COMPANY and the Advisor desire to enter into this Agreement for the performance by Advisor of the consulting and advisory services
to COMPANY under the terms and conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto (collectively, the “Parties”) agree
as follows:

 

1.
APPOINTMENT

 

COMPANY
hereby appoints Advisor, and Advisor accepts such appointment, to perform the consulting and advisory services on behalf of COMPANY.

 

2.
SCOPE OF WORKS

 

2.1
Advisor shall provide the consulting and advisory services as follows (the “Services”):

 

(i)
To introduce products and/or projects listed in Annex 1 (“COMPANY Products/projects”) to pharmaceutical companies
in the areas as described in Annex 1; to assist in evaluation, discussion and negotiation of the terms and conditions of any transaction
contemplated herein from leads provided by Advisor (“Advisor Leads”); and to assist in managing post-transaction communications
with Advisor Leads.

 

(ii)
To find investors.

 

(iii)
To find licensing opportunities for COMPANY Products/projects.

 

2.2
With regards to providing the Services, Advisor promises to use its best effort as reasonably required by a professional advisor
in a same or similar industry.

 

2.3
Notwithstanding anything to the contrary in this Agreement, Advisor shall have no power or authority, express or implied, to enter
into any agreements, understandings, instruments, contracts or proposed transactions on behalf of COMPANY without the prior written
consent of COMPANY.

 

    	 	 	 

    	 

    

 

3.
COMPENSATION

 

3.1
COMPANY shall pay a fixed retainer for the services that Advisor will perform hereunder. The fixed (one time only) retainer will
be invoiced upfront and will be EURO 15.000,- (fifteen thousand) (excluding VAT) for the services rendered hereunder:

 

3.2
Additionally, COMPANY will pay Advisor 2.5% of the net payments received by COMPANY from (a) sales of products or licensing activities
arising directly and exclusively from Advisor Leads made during the term of Agreement and (b) any investors first introduced to
COMPANY and paid to COMPANY during the term of the Agreement.

 

3.3
All payments are payable within twenty (20) days from the invoice date to Advisor’s designated bank account.

 

3.4
COMPANY and Advisor shall each be solely responsible for all local taxes payable with respect to any payments received by them
under this Agreement.

 

3.5
The upfront payment does not cover any travelling/hotel costs in case these have to be made. All costs (if applicable) will be
pre-approved by COMPANY.

 

3.6
Advisor will start the assignment once the upfront payment has been received.

 

4.
TERM AND TERMINATION

 

4.1
This Agreement shall take effect from the Effective Date and remain in full force and effect for a period of twenty four (24)
months.

 

4.2
Notwithstanding the foregoing, in the event either Party is in breach or default of any material term of this Agreement, and said
breach or default continues unremedied for a period of thirty (30) days after such party’s receipt of written notice from
the other Party specifying the grounds of such breach or default, then in addition to all other rights and remedies at law or
in equity, the other Party will have the right to terminate this Agreement immediately upon written notice to the breaching or
defaulting party.

 

5.
STATUS OF ADVISOR

 

Advisor
shall act at all times as an independent contractor. Nothing in this Agreement shall be regarded as creating any other relationship
between the Parties, and Advisor shall have no authority to bind or act as agent for COMPANY or its employees for any purpose.
No employees, staff, or agents of Advisor shall represent themselves to be an employee of COMPANY.

 

    	 	2	 

    	 

    

 

6.
CONFIDENTIALITY

 

6.1
Advisor agrees not to disclose any proprietary information to third parties or use any proprietary information of COMPANY without
the prior written consent of COMPANY. In addition, Advisor shall treat and protect such information in the same manner as it treats
its own information of like character, but with not less than reasonable care, and such information must be immediately returned
to COMPANY upon termination or expiration of this Agreement.

 

6.2
Advisor understands and agrees that its breach or threatened breach of this Article 6 will cause irreparable injury to COMPANY
and that monetary damages alone will not provide an adequate remedy for such breach or threatened breach. The Parties hereby agree
that, in the event of such a breach or threatened breach, the non-breaching party will be also entitled, without the requirement
of posting a bond or other security, to equitable relief, including injunctive relief and specific performance. The Parties’
rights under this Article 6 are cumulative, and a party’s exercise of one right shall not waive the party’s right
to assert any other legal remedy.

 

6.3
The provisions of this Article 6 shall survive the termination or expiration of this Agreement.

 

7.
GENERAL PROVISIONS

 

7.1
Timing and Delivery. Time is of essence. Advisor shall exercise commercially reasonable efforts to provide the Services
for COMPANY in timely manner.

 

7.2
Notice. All notices which either party is required or may desire to give the other party herein shall be sufficiently given
if delivered in person or sent by registered or certified mail, or by prepaid overnight courier, addressed as follows:

 

To
COMPANY at:

248
Route 25A, No. 2, East Setauket, NY 11733

Attention:
John Kovach

 

To
Advisor at:

Heemsteedse
Dreef 159,

2101
KD Heemstede,

The
Netherlands

Attention:
Frans Trouwen

 

7.3
Entire Agreement. This Agreement constitutes the entire agreement between the Parties and any prior understanding or representation
of any kind preceding the date of this Agreement shall not be biding upon either party except to the extent incorporated in this
Agreement.

 

7.4
Modification. No modification or amendment of this Agreement shall be valid unless it is written and signed by the party
against whom the same is sought to be enforced. Notwithstanding the foregoing, COMPANY reserves right to modify the extent and
content of the Services when desired or necessary and Advisor shall not unreasonably withhold or delay its consent to such modification.

 

    	 	3	 

    	 

    

 

7.5
Assignment. Advisor may not assign any of its rights or duties under this Agreement without the prior written consent of
COMPANY.

 

7.6
Force Majeure. The obligations of the Parties under this Agreement shall be suspended if the performance of the obligation
is hindered by strikes, lockouts, war, acts of God, fires, storms, floods, epidemic, accidents, governmental regulations, or the
other cause whatsoever beyond a party’s reasonable control (the “Force Majeure Event”). If a Force Majeure Event
has prevented and continues to prevent implementation of this Agreement for a continuous period of more than six (6) months, such
Force Majeure Event shall be a ground for termination of this Agreement.

 

7.7
Governing Law; Jurisdiction. This Agreement shall be governed in accordance with the laws of England & Wales.

 

7.8
Attorney’s Fees. In the event that any action or proceeding is brought in connection with this Agreement, the prevailing
party shall be entitled to recover its costs and reasonable attorney’s fees.

 

7.9
Counterparts. This Agreement may be executed in any number of counterparts and each of which shall be deemed an original,
but all of which taken together shall constitute one and the same instrument.

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed in duplicate by their duly authorized representatives effective
as of the first written date above.

 

    	 	4	 

    	 

    

 

	Liberi Life Sciences Consultancy BV	 	Lixte Biotechnology Holdings, Inc.	 
	 	 	 	 	 	 
	 	 	 	 
	By:	Drs.
        Frans Trouwen                                                

        
	 	By:	John
Kovach                                      
	 
	Title:	Managing
    Director	 	Title:	CEO	 

 

Annex
1: List COMPANY Products and/or projects and countries

 

Products/Projects:

 

LB-100

 

Countries/Regions:

 

China,
Japan, South Korea

 

    	 	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]